Navigation Links
Raptor Pharmaceuticals Appoints Dr. Patrice P. Rioux as Chief Medical Officer
Date:4/13/2009

Chief Executive Officer and Co-Founder of Raptor, commented, "As a clinical-stage company with multiple active programs, we are pleased to welcome Dr. Rioux. This is an ideal time for Patrice to join Raptor. We believe his successful clinical and regulatory track record will serve us well as we prepare for a pivotal clinical trial in our lead clinical program, DR Cysteamine in cystinosis, and position us to advance our other clinical-stage programs through the clinic and into the market."

Dr. Rioux said, "I am excited to join the team at Raptor, as I believe in the potential of the Company's pipeline of clinical-stage drug candidates that address some serious unmet medical needs."

Status of Raptor's Clinical-Stage Development Programs

Under Dr. Rioux' guidance, the Company expects to conduct its pivotal clinical study for DR Cysteamine in cystinosis in the second half of 2009 and file an NDA in 2010.

In February, 2009, Raptor announced the completion of patient enrollment in its Phase 2a open-label clinical trial to evaluate a prototype formulation of DR Cysteamine in juvenile patients diagnosed with NASH. Results from that study are expected later this year.

In November, 2008, Raptor entered into an agreement with the Centre Hospitalier Universitaire d'Angers ("CHU d'Angers") of France to evaluate DR Cysteamine in a two-year, multi-center Phase II clinical trial in Huntington's, sponsored by CHU d'Angers and supported by a grant from the Programme Hospitalier de Recherche Clinique - National, a program under the French Ministry of Health. Initiation of the Phase II Huntington's study, in which Raptor will supply the study drug, is planned for late 2009.

Also in November 2008, Raptor announced results of its Phase 2a study of Convivia in 32 ALDH2-deficient subjects of Japanese descent. The Company is actively exploring partnering opportunities for Convi
'/>"/>

SOURCE Raptor Pharmaceuticals Corp.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Raptor Pharmaceuticals Announces Completion of Patient Enrollment in Phase 2a Clinical Trial in Non-Alcoholic Steatohepatitis (NASH)
2. Raptor Pharmaceuticals Corp. Announces Positive Phase IIa Clinical Study Results for Convivia(TM) Program
3. Raptor Pharmaceuticals to Collaborate with Centre Hospitalier Universitaire dAngers for Phase II Clinical Trial in Huntingtons Disease
4. Raptor Pharmaceuticals Provides Update on Targeting Platforms
5. Raptor Pharmaceuticals Announces Phase 2a Clinical Trial Initiation in Non-Alcoholic Steatohepatitis (NASH)
6. Raptor Pharmaceuticals Enters Collaboration Agreement with UC San Diego in Liver Disease
7. Raptor Pharmaceuticals Corp. Initiates Phase IIa Clinical Study for Convivia(TM)
8. Raptor Pharmaceuticals Provides Update of Product Programs
9. Strativa Pharmaceuticals Provides Product Pipeline Update
10. Rib-X Pharmaceuticals Novel Antibiotic Delafloxacin Named One of R&D Directions 100 Great Investigational Drugs of 2009
11. Arena Pharmaceuticals to Host Conference Call and Webcast on Monday, March 30, 2009 to Discuss Lorcaserin Pivotal Phase 3 Obesity Trial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/22/2014)... and Markets ( http://www.researchandmarkets.com/research/h3xm6q/us ) has announced ... Market" report to their offering. ... focuses on the developments in the self-monitoring blood glucose ... Reimbursement analysis and the effects of competitive bidding have ... SMBG meters have been performed, based on the various ...
(Date:12/22/2014)... -- Cyberonics, Inc. (NASDAQ: CYBX ), a global ... epilepsy, today announced it will participate in the 33 rd ... 2015, in San Francisco . ... will speak at 11:00 AM Pacific Time.  A live audio ... the Investor Relations link on the Cyberonics home page at ...
(Date:12/22/2014)... ALTO, Calif. , Dec, 22, 2014 /PRNewswire/ ... a Phase 2a study of lonafarnib in patients ... study was conducted at the National Institutes of ... Maryland .  The double-blinded, randomized, placebo-controlled, dose ... mg twice daily and 200 mg twice daily ...
Breaking Medicine Technology:US Self-monitoring Blood Glucose Market 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 2Eiger Bio Announces Positive Data in Patients Infected with Hepatitis Delta Virus (HDV) Treated with Lonafarnib - Results Presented at American Association for the Study of Liver Diseases (AASLD) Meeting 3
... 2011   Radiotherapy Clinics of Georgia has announced the ... physicians of Radiotherapy Clinics of Georgia in January.  These courses ... and treatment options. All Prostate Cancer Lecture Series ... a light dinner at 5 p.m. followed by a lecture ...
... Md., Dec. 16, 2011 The U.S. Food and Drug ... heart of children with heart failure to help keep them ... found. (Logo: http://photos.prnewswire.com/prnh/20090824/FDALOGO ) ... Pediatric System, made by a German company, Berlin Heart. The ...
Cached Medicine Technology:Radiotherapy Clinics of Georgia Present Prostate Cancer Lecture Series 2FDA Approves Mechanical Cardiac Assist Device for Children With Heart Failure 2FDA Approves Mechanical Cardiac Assist Device for Children With Heart Failure 3
(Date:12/24/2014)... News) -- Longer and colder body cooling does not reduce ... from a lack of oxygen, a new study finds. ... condition -- called hypoxic ischemic encephalopathy -- can be reduced ... Fahrenheit) for 72 hours, experts say. Research has shown ... so this study examined if the same would be true ...
(Date:12/24/2014)... Dec. 23, 2014 (HealthDay News) -- Though most patients ... medication and therapy, between 10 percent to 20 percent ... to standard care, experts say. However, patients with ... form of a type of brain surgery that disables ... The challenge: to distinguish between patients most likely to ...
(Date:12/24/2014)... you are a high-risk heart patient, you might be ... cardiologist, new research suggests. Survival rates among these ... professional meetings, Harvard researchers report. Sixty percent of ... teaching hospital during one of these meetings died within ... were not taking place. "That,s a tremendous reduction ...
(Date:12/22/2014)... December 22, 2014 As part ... senior care service in San Diego and ... of its senior care team with ongoing online ... Golden Care is provided by Caregiverlist®. Caregiverlist® ... caregivers with the most reliable eldercare options, highest ...
(Date:12/22/2014)... Los Angeles, CA (PRWEB) December 22, 2014 ... the names have changed. The reason why most fad ... work - temporarily. The problem with fad diets is that, ... loss tapers, leaving the dieter uncertain of how to reset ... mode. For this reason, Diet Doc developed their all-inclusive ...
Breaking Medicine News(10 mins):Health News:Greater Cooling of Oxygen-Deprived Infants Fails to Improve Survival 2Health News:Scans May Spot People Who'll Benefit From Surgery for OCD 2Health News:When Heart Docs Are Away, Their High-Risk Patients May Fare Better 2Health News:When Heart Docs Are Away, Their High-Risk Patients May Fare Better 3Health News:Golden Care Partners with Nationally Recognized Caregiver Training Service 2Health News:Diet Doc Announces the Difference Between Fad Diets and Real Weight Loss Programs to Help Dieters Make the Best Choice 2Health News:Diet Doc Announces the Difference Between Fad Diets and Real Weight Loss Programs to Help Dieters Make the Best Choice 3Health News:Diet Doc Announces the Difference Between Fad Diets and Real Weight Loss Programs to Help Dieters Make the Best Choice 4
... Minyard Food Stores Inc. is offering any,expectant mom ... Life Healthy(TM)" initiative, the company announced,today., Just in ... will,offer free prenatal vitamins to all expectant mothers for ... any Carnival, Minyard or,Sack,n Save store in North Texas. ...
... and other hospital and healthcare advocates from across the,state ... protest the nearly $300,million in healthcare cuts proposed in ... Gone Tomorrow," a Rally to Preserve Our Healthcare, ... WHEN: 12 noon, May 12, The "Care Today, ...
... Consumer,Healthcare, marketer of the leading smoking cessation products ... applauds,the release of the updated 2008 U.S. Public ... Dependence. Too many smokers lower their,chances of quitting ... The Guideline is an important validation of the ...
... Vaccinogen Inc. said Dutch health,authorities licensed it to manufacture ... to more than $100 million of,potential European sales., ... Emmen, The,Netherlands also paves the way to its pivotal ... before the vaccine can be sold in the United,States., ...
... 7 Hamline University School of Law,s,Health Law Institute ... offer a Health Care Corporate Compliance Certificate,education program. Hamline,s ... the Upper Midwest and one of only four programs ... program is designed to be completed within,one year, with ...
... studies indicate improved IVF procedures may spare patients money & ... ... Calif., May 7 Spurred by recent research,California fertility specialists are ... -- saying newer,and improving in vitro fertilization (IVF) technology tends to ...
Cached Medicine News:Health News:Expectant Moms Offered Free Prenatal Prescription Vitamins at D-FW Area Carnival, Minyard and Sack'n Save Stores 2Health News:A Statement from GlaxoSmithKline Consumer Healthcare on 2008 Update to the U.S. Public Health Service Guideline on Treating Tobacco Use and Dependence 2Health News:A Statement from GlaxoSmithKline Consumer Healthcare on 2008 Update to the U.S. Public Health Service Guideline on Treating Tobacco Use and Dependence 3Health News:Dutch Authorize Manufacture of Vaccinogen's New Cancer Vaccine; License Clears Path to European Production, Final FDA Trial 2Health News:Fertility Doctors: Studies Suggest Artificial Insemination Increasingly Second Choice 2
... aerosol contamination, which causes ... PCR. Hydrophobic, nonwicking and ... can pass through these ... contrast to tips with ...
Inquire...
... are ideal for PCR and ... any work where aerosol contamination ... for pipetting DNA/RNA solutions, infectious ... For applications requiring absolute sterility, ...
... Finntip Filters are ideal ... methods, or for any work ... They are designed for pipetting ... samples, and other. For applications ...
Medicine Products: